Document is current
Any future updates will be listed below
-
Authors
Stanescu, S. https://orcid.org/0000-0003-0340-4580
Belanger-Quintana, A.
Rocha, J. C.
Almeida, M. F.
Ahring, K.
Dokoupil, K.
Lammardo, A. M.
van Dam, E.
Muriel, A.
MacDonald, A.
,
Belanger-Quintana, A.
Dokoupil, K.
Ahring, K.
Rocha, J. C.
GokmenOzel, H.
Robert, M.
van Dam, E.
Lammardo, A. M.
MacDonald, A.
- License Information
-
More Information
Article History
Received: 10 April 2025
Accepted: 22 July 2025
First Online: 4 August 2025
Declarations
:
: This is a retrospective historical study, therefor the verbal consent was obtained from the patients to access their data.
: Not applicable.
: SS has no conflict of interest in relation to the content of this study. She has received speaker and travel honoraria from Nutricia, Vitaflo and Sanofi. ABQ has no conflict of interest in relation to the content of this study. She is participating in several clinical essays relating to PKU and has been part of advisory boards for PTC Therapeutics, BioMarin and Nutricia regarding this disease. She has received speaker honoraria, travel, investigation or meeting funds from these companies, as well as from Danone, Recordati Rare Diseases, Grand Fontaine and other industries not related to PKU. JCR was a member of the European Nutritionist Expert Panel (Biomarin), the Advisory Board for Applied Pharma Research, Vitaflo, Synlogic, Biomarin, PTC and Nutricia, and received honoraria as speaker from APR, Merck Serono, Biomarin, Nutricia, Vitaflo, Cambrooke, PIAM and Lifediet. The rest of the authors have no conflict of interest to declare in relation to this study.
